Please login to the form below

Not currently logged in
Email:
Password:

Accelerated approval not working

The US FDA's accelerated approval programme for NMEs is not achieving its aim, according to a multi-centre study

The US Food and Drug Administration's (FDA's) accelerated approval programme for new molecular entities (NMEs) is not achieving its aim, according to a multi-centre study published in the Journal of Clinical Oncology.

The initiative was set up in 1992 to try to speed up access to therapies for life-threatening conditions, including cancer. Researchers looked at data for accelerated and regular FDA approvals in oncology since 1995. The study shows that oncology NMEs in the accelerated programme reached market in a median time of 7.3 years and new drugs going through regular approval took a median of 7.2 years.

One of the problems, particularly for small biotech companies, is the cost of the large-scale studies now required by the regulators. The authors call for the FDA to return to basing approval for potentially life-saving drugs on smaller studies, in order to expedite access to new treatments for patients with terminal conditions.

28th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics